MedTrace Logo

T Central Memory Cells in Early Localized Non-Segmental Vitiligo

NCT05706636 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-04-25

No results posted yet for this study

Summary

Assessing the level of circulating TCMs (cluster of differentiation (CD) 8+, CD3+,C- chemokine receptor (CCR)7, cluster of differentiation 45 receptor (CD45R) cells) in early localized vitiligo cases prior to treatment and after treatment in comparison to healthy controls. This, in turn, would provide insights regarding the role of TCMs in vitiligo and the role of early treatment in halting disease progression and autoimmune memory formation that accounts for high recurrence rate of vitiligo

Conditions

  • Vitiligo

Interventions

DRUG

oral mini pulse

5mg / week oral dexamethasone

DRUG

Topical cream

topical fluticasone cream for body lesions and topical tacrolimus for face lesions

DEVICE

targeted phototherapy

twice weekly targeted excimer light sessions

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Samia Esmat, MD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2024-12-01
Completion
2025-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05706636 on ClinicalTrials.gov